New drug combo targets genetic weaknesses in head and neck cancer
Disease control
Completed
This study tested a combination of two drugs, tipifarnib and alpelisib, in 45 adults with advanced head and neck cancer that had spread or come back. The drugs target specific genetic changes in the tumor (HRAS overexpression or PIK3CA mutations/amplification). The main goals wer…
Phase: PHASE1, PHASE2 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 07, 2026 18:38 UTC